Updated on 23 December 2015
Nohla Therapeutics, a developer of cellular therapies for haematological disorders and immunological diseases
Singapore: Nohla Therapeutics, a developer of cellular therapies for haematological disorders and immunological diseases, has raised over $21 million from several institutional investors.
In conjunction with this capital raising, Nohla has appointed Mr Lawrence Gozlan among the Board of Directors. Mr Gozlan is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. With 15 years of experience in investing and banking, Mr Gozlan has expertise in all areas of investment management and deep roots in the scientific and biotech communities. Prior to Scientia Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (the Queensland Investment Corporation), an investment fund with over AUD60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained corporate finance experience advising life science companies at Deloitte.
"I am delighted to join the Board of Nohla Therapeutics", said Mr Gozlan, "The cellular therapy platform developed by Dr Colleen Delaney and Dr Irwin Bernstein at the Fred Hutch provides an unmatched clinical and commercial advantage over all other approaches currently being developed in the fields of stem cell transplant and immuno-oncology. The clinical data generated thus far is exceptional and the technology platform has the potential to be the cornerstone of next generation cellular therapies."
Mr Michael Sistenich, chief business officer, Nohla stated, "We are delighted that Lawrence has agreed to lend his experience and expertise to Nohla. His leadership in the biotech sector will be invaluable to Nohla in the years ahead as we aim to transform the treatment paradigm of stem cell transplants and build a broad pipeline of innovative allogeneic immunotherapies."